2:54 PM
Sep 25, 2017
 |  BC Extra  |  Company News

Gilead's Sovaldi gets Chinese approval

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older.

Gilead said the nucleotide analog HCV NS5B polymerase inhibitor is the first HCV drug from the company to receive Chinese approval. Last year, CFDA selected Sovaldi for expedited review along with Gilead's Harvoni ledipasvir/sofosbuvir, a fixed-dose combination of Sovaldi and ledipasvir, an HCV NS5A protein...

Read the full 375 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >